ObjectiveTo assess the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) treatment and the risk of suicide attempts in people with type 2 diabetes (T2D), with a focus on subgroups with and without a history of depression or suicide attempts.MethodsThis retrospective cohort study utilized TriNetX, a federated network of real‐world data. Using the Global Collaborative Network data, we collected electronic medical records from 113 health care organizations with 135 million patient records with 8 million with T2D, 83% from the United States. The four cohorts were identified based on age, medication, diagnosis, and presence of depression or suicide attempts. Analytic methods included measures of association and number of Instances, with propensity score matching employed to mitigate potential confounders. The primary outcome was the incidence of suicide attempts among people with T2D with GLP‐1RA treatment in comparison with dipeptidyl peptidase‐4 inhibitor (DPP‐4i) treatment.ResultsPeople with T2D treated with GLP‐1RA consistently exhibited a lower risk of suicide attempts compared to those treated with DPP‐4i. This was particularly significant in people with a history of depression or suicide attempts. The risk and odds ratios were significantly lower in the GLP‐1RA‐treated cohorts than in DPP‐4i across all analyses.ConclusionAs compared with DPP‐4i, our analysis shows a protective effect associated with GLP‐1RA treatment on the risk of suicide attempts among people with T2D. However, further research, particularly prospective and randomized studies, is necessary to confirm these observations and understand the underlying mechanisms.image

中文翻译：

---

GLP-1RA 治疗对成年 2 型糖尿病患者自杀企图的影响：基于全球 TriNetX 健康研究数据库的回顾性比较有效性研究

目的评估胰高血糖素样肽 1 受体激动剂 (GLP-1RA) 治疗与 2 型糖尿病 (T2D) 患者自杀未遂风险之间的关联，重点关注有或没有抑郁症或自杀未遂史的亚组方法这项回顾性队列研究利用了 TriNetX，一个真实世界数据的联合网络。使用全球协作网络数据，我们从 113 个医疗保健组织收集了电子病历，其中包含 1.35 亿份患者记录，其中 800 万份 T2D 患者记录，其中 83% 来自美国。这四个队列是根据年龄、药物治疗、诊断以及是否存在抑郁或自杀企图来确定的。分析方法包括关联性和实例数量的测量，并采用倾向得分匹配来减轻潜在的混杂因素。主要结局是与二肽基肽酶 4 抑制剂 (DPP-4i) 治疗相比，接受 GLP-1RA 治疗的 T2D 患者自杀企图的发生率。结果与接受 GLP-1RA 治疗的 T2D 患者相比，接受 GLP-1RA 治疗的 T2D 患者始终表现出较低的自杀企图风险。对于接受 DPP-4i 治疗的患者。这对于有抑郁症或自杀未遂史的人来说尤其重要。在所有分析中，GLP-1RA 治疗组的风险和比值比均显着低于 DPP-4i。结论与 DPP-4i 相比，我们的分析显示 GLP-1RA 治疗对自杀未遂风险具有保护作用患有 T2D 的人。然而，需要进一步的研究，特别是前瞻性和随机研究来证实这些观察结果并了解潜在的机制。图像